GLYCOPYRROLATE MSDS PDF

SAFETY DATA SHEET. PRODUCT: Glycopyrrolate Injection USP. Section 1: PRODUCT AND COMPANY INFORMATION. 54/1, Boodhihal village,. Nelamangala. Glycopyrrolate. 1-Methylpyrrolidyl alpha-phenylcyclopentaneglycolate methobromide;. Glycopyrrolate bromide; Glycopyrronium bromide. Glycopyrronium (as the bromide salt glycopyrrolate) is a synthetic anticholinergic agent In October , glycopyrrolate was approved by the FDA for use as a FDA label. Download ( KB). MSDS. Download ( KB).

Author: Dasho Tozil
Country: Luxembourg
Language: English (Spanish)
Genre: Business
Published (Last): 24 December 2017
Pages: 376
PDF File Size: 12.77 Mb
ePub File Size: 9.48 Mb
ISBN: 710-9-43793-193-9
Downloads: 95603
Price: Free* [*Free Regsitration Required]
Uploader: Kazragor

The risk or severity of adverse effects can be increased when Methscopolamine is combined with Glycopyrronium. Timepidium The risk or severity of adverse effects can be increased when Timepidium is combined with Glycopyrronium. Metharbital Metharbital may increase the anticholinergic activities of Glycopyrronium. Cisplatin The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Cisplatin.

Glycopyrronium – DrugBank

Magnesium cation The therapeutic efficacy of Magnesium cation can be decreased when used in combination with Glycopyrronium. The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Gentamicin.

Doxofylline The risk or severity of Tachycardia can be increased when Glycopyrronium is combined with Doxofylline. Oxymetazoline The risk or severity of Tachycardia can be increased when Oxymetazoline is combined with Glycopyrronium.

Butethal Glycopyrronium may glycopyrrolatd the anticholinergic activities of Butethal. The risk or severity of Tachycardia can be increased when Glycopyrronium is combined with Octopamine.

  EF12 TUBE PDF

The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Diphenoxylate. Bupropion Glycopyrronium may increase the anticholinergic activities of Bupropion.

The risk or severity of Tachycardia can be increased when Glycopyrronium msxs combined with Chlorphentermine. Carboxymethylcellulose The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Glycopyrronium. The risk or severity of adverse effects can be increased when Aripiprazole is combined with Glycopyrronium. Calcium polycarbophil The therapeutic efficacy of Calcium polycarbophil can be decreased when used in combination with Glycopyrronium.

Potassium Guaiacolsulfonate The therapeutic efficacy of Potassium Guaiacolsulfonate can be decreased when used in combination with Glycopyrronium. Oxyphenonium The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Glycopyrronium.

Sufentanil The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Sufentanil. The risk or severity of adverse effects can be increased when Poldine is combined with Glycopyrronium. The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Aprotinin. The risk or severity of adverse effects can be increased when Atropine is combined glycophrrolate Glycopyrronium.

Talbutal Talbutal may increase the anticholinergic activities of Glycopyrronium. Cyclopentolate The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Glycopyrronium. Procaine The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Procaine.

  GUA DE INTERPRETACIN DEL TEST DE WARTEGG PDF

Glycopyrronium

Gallamine Glycopyrronium may increase the anticholinergic activities of Gallamine. The risk or severity of Tachycardia and drowsiness can be increased when Glycopyrronium is combined with Nabiximols. Metocurine The risk or severity of adverse effects can be increased when Metocurine is combined with Glycopyrronium. Benzilone The risk or severity of adverse effects can be increased when Benzilone is combined with Glycopyrronium.

Glycoyprrolate The risk or severity of Tachycardia can be increased when Etomidate is combined with Glycopyrronium. Emodin The therapeutic efficacy of Emodin can be decreased when used in combination with Glycopyrronium. Xamoterol The risk or severity of Tachycardia can be increased when Glycopyrronium is combined with Xamoterol. The therapeutic efficacy of Docusate can be decreased when used in combination with Glycopyrronium. The risk or severity of adverse effects can be increased when Imipramine is combined with Glycopyrronium.

The risk or severity of Tachycardia can be increased when Dobutamine is combined with Glycopyrronium.